CJC-1295 (No DAC) + Ipamorelin 10 mg Blend

Growth hormone axis Research compound (not approved for human use)

Growth-hormone axis blend · also known as CJC/Ipamorelin

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

This blend pairs a GHRH analog (CJC-1295 No DAC) with a ghrelin-mimetic secretagogue (Ipamorelin) in one vial. The two act on different receptors, which is why they are commonly combined in growth-hormone research protocols.

Commonly reported dosing (10 mg vial)

Reconstituted with 3 mL → 3.333 mg/mL.

Phase	Dose	Volume	U-100 units
Starting Weeks 1-2; total blend (about 100 mcg of each peptide).	200 mcg	0.06 mL	6
Step Weeks 3-4; total blend (about 150 mcg of each).	300 mcg	0.09 mL	9
Standard Weeks 5-6; total blend (about 200 mcg of each).	400 mcg	0.12 mL	12
Higher Weeks 7-12; total blend (about 250-300 mcg of each).	600 mcg	0.18 mL	18

Each 200 mcg draw contains 100 mcg CJC-1295 (No DAC) + 100 mcg Ipamorelin.

Frequency: Once daily, commonly before bed or on waking (some reports use 2x daily), subcutaneous · Half-life: Mixed (short)

Open in calculator

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 10 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 3.33 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Sealed vials are commonly stored refrigerated (2-8 °C) and protected from light, or frozen for long-term storage.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and not frozen.

Commonly used within 28 days of mixing.

How it works

CJC-1295 amplifies the GHRH signal while Ipamorelin acts on the ghrelin/GHS receptor; the combined effect is studied for a larger growth-hormone pulse than either alone.

Researched for

Studied for amplified GH pulses.
Studied as a combined CJC-1295 and Ipamorelin protocol.

Notes

Timing before sleep is a common research variable.
Typical amounts correspond to small volumes on a U-100 syringe.
The reference chart lists per-peptide amounts, but its syringe-unit column corresponds to total-blend amounts; the figures here are totals for both peptides together.